Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/1999
10/19/1999US5969184 Amide compounds
10/19/1999US5969156 Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/19/1999US5969151 Pyrazole compounds
10/19/1999US5969146 Monoamine oxidase inhibitors
10/19/1999US5969132 Macrocyclic difluorostatone derivatives useful as antiviral agents
10/19/1999US5969126 GNRH-leukotoxin chimeras
10/19/1999US5969120 Dna molecule with synthetically mutated retinoblastoma gene encoding a mutated protein; therapy for a tumor cell with mutation in cyclin gene; antitumor agents
10/19/1999US5969095 Analogs of parathyroid hormone
10/19/1999US5969093 Secreted proteins
10/19/1999US5969017 Methods of treating or preventing cardiac arrhythmia
10/19/1999US5968983 Administering a mixture of arginine and an inhibitor of a reductase
10/19/1999US5968978 Antiarrythmia agents, antiischemic agents, inhibit proliferation of cells
10/19/1999US5968971 Endothelin receptor antagonists
10/19/1999US5968970 Treatment of hiv
10/19/1999US5968969 Stable, long acting salts of carboxamides for the treatment of joint disease
10/19/1999US5968963 PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
10/19/1999US5968959 Administering phospholamban inhibitor
10/19/1999US5968957 Administering to effect neuronal activity
10/19/1999US5968954 Exhibit selective binding affinity for 5-hydroxytryptamine receptors
10/19/1999US5968952 Farnesyl transferase inhibiting 2-quinolone derivatives
10/19/1999US5968950 Treatment of hypertriglyceridemia with decreasing apo b secretion for treatment of atheriosclerosis, pancreatitis, obesity or diabetes
10/19/1999US5968945 Immunotherapeutic agents
10/19/1999US5968944 Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists
10/19/1999US5968934 Treatment of pain, inflammation, migraines, emesis and postherapeutic neuralgia
10/19/1999US5968932 Method of inhibiting sleep apnea
10/19/1999US5968924 Benzo-fused lactams promote release of growth hormone
10/19/1999US5968923 (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
10/19/1999US5968921 Compositions and methods for promoting nerve regeneration
10/19/1999US5968920 Increase glutathione peroxidase activity for reducing levels of peroxides in cells or tissues
10/19/1999US5968913 Pharmaceutical compositions of uridine triphosphate
10/19/1999US5968907 1-thiogalactose derivatives
10/19/1999US5968903 Helicobacter and antigrowth agents, using somatostatin or agonist
10/19/1999US5968826 Antisense inhibition of integrin α4 expression
10/19/1999US5968824 Administering agent which modulates biochemical pathway in which products of opioid peptide precursor genes participate; antitumor agents; prevention of opacity of intraocular lens after cataract surgery
10/19/1999US5968822 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
10/19/1999US5968819 DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
10/19/1999US5968780 Dendritic cell-derived growth factor
10/19/1999US5968764 Detecting modulators of glucose transport protein; therapy for diabetes and disorders of insulin resistance, by incubating glucose transport protein with test compound, adding transport protein substrate, monitoring effect
10/19/1999US5968752 Method for identifying an OP-1 analog which binds an ALK-1 receptor
10/19/1999US5968737 Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
10/19/1999US5968532 Substance p antagonists
10/19/1999CA2197298C Novel pyrimidine derivatives and processes for the preparation thereof
10/17/1999CA2269262A1 Substituted tricyclics
10/17/1999CA2269256A1 Substituted tricyclics
10/16/1999CA2269049A1 N-acyl and n-aroyl aralkyl amides
10/14/1999WO1999051751A1 Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
10/14/1999WO1999051638A1 DUAL Avb3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS
10/14/1999WO1999051626A2 Template associated npy y2-receptor agonists
10/14/1999WO1999051613A1 Prodrugs of phosphorous-containing pharmaceuticals
10/14/1999WO1999051608A1 THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
10/14/1999WO1999051605A1 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR
10/14/1999WO1999051602A1 Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
10/14/1999WO1999051601A1 Azatricyclic compounds
10/14/1999WO1999051600A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES
10/14/1999WO1999051599A1 Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
10/14/1999WO1999051596A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051595A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051594A1 IMIDAZO[1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS
10/14/1999WO1999051580A1 Pyrazole inhibitors of cytokine production
10/14/1999WO1999051571A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
10/14/1999WO1999051569A1 Calcilytic compounds
10/14/1999WO1999051564A1 Propanolamine derivatives
10/14/1999WO1999051271A2 Compositions comprising glycol derivatives and alcohols
10/14/1999WO1999051267A1 Hiv-specific cytotoxic t-cell responses
10/14/1999WO1999051262A2 Use of igfi for treating articular cartilage disorders
10/14/1999WO1999051260A2 Treatment of cardiac hypertrophy
10/14/1999WO1999051258A1 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE
10/14/1999WO1999051257A1 Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
10/14/1999WO1999051254A1 Short peptides for treatment of neurological degenerative diseases
10/14/1999WO1999051244A1 Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
10/14/1999WO1999051243A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
10/14/1999WO1999051242A1 Medicinal compositions for treating edema
10/14/1999WO1999051240A1 Acylbenzoxazines for enhancing synaptic response(s)
10/14/1999WO1999051236A1 Methods for inhibiting mrp1
10/14/1999WO1999051228A1 Methods for inhibiting mrp1
10/14/1999WO1999051227A1 Methods for inhibiting mrp1
10/14/1999WO1999051220A1 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin
10/14/1999WO1999051217A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
10/14/1999WO1999051216A2 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
10/14/1999WO1999051215A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
10/14/1999WO1999051185A2 Human galactosyl transferases
10/14/1999WO1999051097A1 Compositions containing a combination of a creatine compound and a second agent
10/14/1999WO1999045011A8 Glycine transport inhibitors
10/14/1999WO1999044623A8 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
10/14/1999WO1999043361A8 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
10/14/1999WO1999042579A3 Caf1-related protein
10/14/1999WO1999042089A3 Use of thiadiazolo[4,3-a]pyridine derivatives
10/14/1999WO1999042075A3 Antibodies against human cd40
10/14/1999WO1999039729A3 Use of heregulin as an epithelial cell growth factor
10/14/1999WO1999039702A3 Method for regulating size and growth of vascularized normal tissue
10/14/1999WO1999037660A9 Meth1 and meth2 polynucleotides and polypeptides
10/14/1999WO1999033840B1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action
10/14/1999WO1999028343A9 Hydrophobically-modified protein compositions and methods
10/14/1999WO1999027937A3 Method for inhibiting cytokine production by cells
10/14/1999WO1999026660A3 Conjugates of cytokines and drugs or genes for treating proliferating cells
10/14/1999WO1999026604A3 Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood
10/14/1999DE19815060A1 Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie Pharmaceutical preparations for the therapy of side effects during and / or after a GnRHa therapy
10/14/1999DE19814084A1 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's disease and process for its preparation
10/14/1999DE19807426A1 Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs A method for the treatment of diseases or disorders of the inner ear
10/14/1999CA2327811A1 Short peptides for treatment of neurological degenerative diseases
1 ... 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 ... 1564